Progenics and Wyeth Announce Positive Results from Three-Month
Clinical-Extension Study of Subcutaneous Methylnaltrexone for the
Treatment of Opioid-Induced Constipation in Patients with Advanced
Illness
TARRYTOWN, N.Y. & MADISON, N.J.--(BUSINESS WIRE)--Jun 28, 2007-
Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX) and WyethPharmaceuticals, a division of Wyeth (NYSE: WYE), today announcedpositive results from a three-month open-label extension study ofsubcutaneous methylnaltrexone for the treatment of opioid-inducedconstipation (OIC) in patients with advanced illness. The resultsare sched...
Progenics Announces Positive Results in Clinical Trial of Novel HIV
Therapy
TARRYTOWN, N.Y.--(BUSINESS WIRE)--May 1, 2007 -
ProgenicsPharmaceuticals, Inc. (NASDAQ: PGNX) today announced positiveresults from the first clinical trial of its investigational drug,PRO 140, in individuals infected with the human immunodeficiencyvirus (HIV), the causative agent of AIDS. Patients receiving asingle 5.0 mg/kg dose of PRO 140 achieved an average maximumdecrease of viral conce...